Evidence map›Paper›PMID 37603199›Full record

ReviewClinical reviews in allergy & immunology2023

Treatable Traits in Systemic Sclerosis.

Francesco Amati, Gabriele Bongiovanni, Antonio Tonutti, Francesca Motta, Anna Stainer, Giuseppe Mangiameli, Stefano Aliberti, Carlo Selmi, Maria De Santis

Abstract readReview
PubMed Publisher
In one paragraph

Review in Clinical reviews in allergy & immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Francesco AmatiDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Gabriele BongiovanniDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Antonio TonuttiDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Francesca MottaDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Anna StainerDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Giuseppe MangiameliDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Stefano AlibertiDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Carlo SelmiDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy. carlo.selmi@hunimed.eu.
Maria De SantisDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Humanitas University · ITIRCCS Humanitas Research Hospital · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Systemic sclerosis (SSc) is a chronic systemic disease within the spectrum of connective tissue diseases, specifically characterized by vascular abnormalities and inflammatory and fibrotic involvement of the skin and internal organs resulting in high morbidity and mortality. The clinical phenotype of SSc is heterogeneous, and serum autoantibodies together with the extent of skin involvement have a predictive value in the risk stratification. Current recommendations include an organ-based management according to the predominant involvement with only limited individual factors included in the treatment algorithm. Similar to what has been proposed for other chronic diseases, we hypothesize that a "treatable trait" approach based on relevant phenotypes and endotypes could address the unmet needs in SSc stratification and treatment to maximize the outcomes. We provide herein a comprehensive review and a critical discussion of the literature regarding potential treatable traits in SSc, focusing on established and candidate biomarkers, with the purpose of setting the bases for a precision medicine-based approach. The discussion, structured based on the organ involvement, allows to conjugate the pathogenetic mechanisms of tissue injury with the proposed predictors, particularly autoantibodies and other serum biomarkers. Ultimately, we are convinced that precision medicine is the ideal guide to manage a complex condition such as SSc for which available treatments are largely unsatisfactory.

Indexed as

Scleroderma, SystemicAutoantibodiesBiomarkersHumansPhenotypePrecision MedicineSkinAutoantibodiesBiomarkersAutoimmune disorderSystemic sclerosisTreatable trait

Identifiers

PMID37603199
OpenAlexW4386019642

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.